Cardiotoxicity associated with targeted cancer therapies (Review)

  • Authors:
    • Zi Chen
    • Di Ai
  • View Affiliations

  • Published online on: March 3, 2016     https://doi.org/10.3892/mco.2016.800
  • Pages: 675-681
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in carcinogenesis and tumor spread are inhibited. Targeted cancer therapy has fewer adverse effects on normal cells and is considered to be the future of chemotherapy. However, targeted cancer therapy‑induced cardiovascular toxicities are occasionally critical issues in patients who receive novel anticancer agents, such as trastuzumab, bevacizumab, sunitinib and imatinib. The aim of this review was to discuss these most commonly used drugs and associated incidence of cardiotoxicities, including left ventricular dysfunction, heart failure, hypertension and thromboembolic events, as well as summarize their respective molecular mechanisms of cardiovascular adverse effects.
View References

Related Articles

Journal Cover

May 2016
Volume 4 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, Z., & Chen, Z. (2016). Cardiotoxicity associated with targeted cancer therapies (Review). Molecular and Clinical Oncology, 4, 675-681. https://doi.org/10.3892/mco.2016.800
MLA
Chen, Z., Ai, D."Cardiotoxicity associated with targeted cancer therapies (Review)". Molecular and Clinical Oncology 4.5 (2016): 675-681.
Chicago
Chen, Z., Ai, D."Cardiotoxicity associated with targeted cancer therapies (Review)". Molecular and Clinical Oncology 4, no. 5 (2016): 675-681. https://doi.org/10.3892/mco.2016.800